Cwm LLC Has $6.44 Million Stock Position in Sanofi (NASDAQ:SNY)

Cwm LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 1.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 132,587 shares of the company’s stock after selling 2,240 shares during the period. Cwm LLC’s holdings in Sanofi were worth $6,444,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Boston Partners boosted its stake in Sanofi by 1.9% during the 4th quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after purchasing an additional 245,682 shares during the period. Morgan Stanley boosted its stake in Sanofi by 4.6% during the 3rd quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after purchasing an additional 323,968 shares during the period. Envestnet Asset Management Inc. boosted its stake in Sanofi by 29.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock valued at $152,279,000 after purchasing an additional 651,756 shares during the period. Natixis Advisors L.P. boosted its stake in Sanofi by 15.9% during the 3rd quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after purchasing an additional 346,563 shares during the period. Finally, Brandes Investment Partners LP boosted its stake in Sanofi by 64.6% during the 4th quarter. Brandes Investment Partners LP now owns 1,770,572 shares of the company’s stock valued at $88,051,000 after purchasing an additional 694,957 shares during the period. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of SNY stock opened at $47.22 on Thursday. The stock has a 50 day moving average of $48.32 and a two-hundred day moving average of $48.49. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.72. The company has a market capitalization of $119.46 billion, a P/E ratio of 23.73, a P/E/G ratio of 1.48 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.96 EPS for the quarter, hitting analysts’ consensus estimates of $0.96. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. The company had revenue of $11.36 billion during the quarter, compared to the consensus estimate of $11.75 billion. As a group, equities analysts expect that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, June 6th. Shareholders of record on Friday, May 10th were given a $1.478 dividend. The ex-dividend date was Thursday, May 9th. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is currently 74.37%.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.